Research Analysts at Needham Kept the Same their “Buy” rating for Ionis Pharmaceuticals (IONS). The Target Given is $67.0000; AIMIA COMMON SHARES CANADA (GAPFF) SI Increased By 114.45%

Aimia Inc. (OTCMKTS:GAPFF) Logo

Needham currently has a $67.0000 PT on the $6.09 billion market cap company or 38.12% upside potential. In a note revealed to investors and clients on Friday morning, Ionis Pharmaceuticals Inc (IONS) stock had its “Buy” Rating restate by investment analysts at Needham.

AIMIA INC COMMON SHARES CANADA (OTCMKTS:GAPFF) had an increase of 114.45% in short interest. GAPFF’s SI was 4.79M shares in April as released by FINRA. Its up 114.45% from 2.24 million shares previously. With 257,900 avg volume, 19 days are for AIMIA INC COMMON SHARES CANADA (OTCMKTS:GAPFF)’s short sellers to cover GAPFF’s short positions. The SI to AIMIA INC COMMON SHARES CANADA’s float is 3.15%. The stock increased 1.48% or $0.02 during the last trading session, reaching $1.37. About 136,672 shares traded or 9.91% up from the average. Aimia Inc. (OTCMKTS:GAPFF) has 0.00% since April 21, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to report earnings on May, 8. They expect $-0.11 EPS, down 466.67% or $0.14 from last year’s $0.03 per share. After $0.02 actual EPS reported by Ionis Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -650.00% negative EPS growth.

The stock increased 5.80% or $2.66 during the last trading session, reaching $48.51. About 4.48 million shares traded or 300.63% up from the average. Ionis Pharmaceuticals, Inc. (IONS) has risen 14.82% since April 21, 2017 and is uptrending. It has outperformed by 3.27% the S&P500.

Among 14 analysts covering Ionis Pharmace… (IONS), 6 have Buy rating, 1 Sell and 7 Hold. Therefore 43% are positive. Ionis Pharmace… has $7500 highest and $25 lowest target. $54.50’s average target is 12.35% above currents $48.51 stock price. Ionis Pharmace… had 39 analyst reports since April 7, 2016 according to SRatingsIntel. The stock has “Buy” rating by BMO Capital Markets on Thursday, January 25. As per Wednesday, July 26, the company rating was maintained by BMO Capital Markets. The firm earned “Outperform” rating on Wednesday, December 28 by BMO Capital Markets. The firm has “Buy” rating given on Friday, April 20 by BMO Capital Markets. The rating was initiated by Janney Capital on Thursday, September 29 with “Buy”. The firm has “Hold” rating given on Tuesday, August 8 by Cowen & Co. The firm earned “Buy” rating on Thursday, June 1 by BMO Capital Markets. The firm earned “Outperform” rating on Wednesday, February 28 by BMO Capital Markets. The stock of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) earned “Mkt Perform” rating by Leerink Swann on Tuesday, December 27. The stock of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has “Hold” rating given on Friday, October 13 by Stifel Nicolaus.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company has market cap of $6.09 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and as an adjunct to lipid lowering medications and diet. It currently has negative earnings. The Company’s drugs in Phase III development include volanesorsen for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug for transthyretin amyloidosis.

Aimia Inc., through its subsidiaries, operates as a data-driven marketing and loyalty analytics firm worldwide. The company has market cap of $199.22 million. It operates through Americas Coalitions, International Coalitions, and Global Loyalty Solutions divisions. It currently has negative earnings. The firm owns and operates the Aeroplan Program, a coalition loyalty program in Canada, as well as non-platform based loyalty services business; the Nectar UK and Air Miles Middle East coalition loyalty programs; and Travel Club, a coalition loyalty program in Spain.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Ratings Chart